Interleukin-2 Production of T Cells in Atopic Dermatitis

Abstract

Patients with atopic dermatitis (AD) were treated with Tranilast, Interleukin-2 (IL-2) (production of T cells in vitro) and blood histamine values, before and after Tranilast therapy, were measured, and the following results were obtained: 1) Compared with healthy controls, the IL-2 producing ability of T cells in patients with AD was increased. 2) After Tranilast therapy, IL-2 production of T cells in AD decreased in quantity to the control level. 3) Skin lesion severities of AD were correlated with the quantity of IL-2 production of T cells. 4) Serum histamine levels were not significantly different between AD patients and healthy controls, before or after Tranilast therapy.

Cyclosporin‐A in the treatment of atopic dermatitis: effects on the immune system and clinical efficiency

“…Furthermore, the CD2 count was different from other studies where the number of CD2 has been shown to be decreased [9]. Normalization of CD25 after therapy confirm the role of CD25 -I-lymphocytes in the pathogenesis of atopic dermatitis [10][11][12][13]; the role of HLA-DR and Langerhans cells is uncertain [14][15][16]. Our study demonstrated that the group of patients that gradually reduced the doses of CyA, showed a slower or abolished expression of HLA-DR and IL-2-receptor, probably due to longer immunmodulation of CyA.The low level of CD 16 is probably correlated with a greater susceptibility of atopic patients to viral infection [17].…”

Inhibition of Interleukin-1β-Induced Matrix Metalloproteinase Expression in Human Corneal Fibroblasts by Tranilast

“…Tranilast and steroids exert various effects on immune cells as well as on tissue resident cells that participate in inflammatory responses. Both steroids and tranilast thus inhibit cytokine synthesis in T cells 47,48 and macrophages. 49,50 Both inhibit MMP production by fibroblasts 3,18 and neutrophils, 19,51 whereas steroids also inhibit phagocytosis by neutrophils.…”

Potential Aspects of the Use of Cytokines in Atopic Dermatitis

“…Morita et al revealed that patients with AD have a higher level of IL-2 in the blood and IL-2 production by T-cells is higher in this group of patients. Treatment using Tranilast (N-3, 4-dimethoxycinnamoyl anthranilic acid) provides a decrease in the IL-2 production of T cells in AD patients [134]. Tranilast, thanks to its anti-allergic properties, was approved in Japan and South Korea in 1982 for the treatment of bronchial asthma, keloid, and hypertrophic scar, but currently has no approval in the United States or elsewhere.…”